Sign in

    Roger A. Jeffs

    Chief Executive Officer at Liquidia Corp
    Board
    Since January 2022
    Age
    63 years
    Education
    Holds a Ph.D., although details regarding the institutions or field of study are not provided.
    Tenure
    Joined LQDA as a Board Member in November 2020 and began serving as Chief Executive Officer in January 2022.

    Also at Liquidia Corp

    JA
    Jason Adair
    Chief Business Officer
    MK
    Michael Kaseta
    Chief Operating Officer (COO)
    RS
    Rajeev Saggar
    Chief Medical Officer

    About

    Roger A. Jeffs, Ph.D. is the Chief Executive Officer of Liquidia Corporation (LQDA), having assumed the role in January 2022 after initially joining as a Board Member in November 2020.

    With an extensive background in the biotechnology and pharmaceutical sectors, he has previously held senior roles at United Therapeutics Corporation, where he contributed to the commercialization and development of multiple pharmaceutical products over an 18-year career. His leadership experience spans roles including President, Chief Operating Officer, and co-CEO, which underscores his proficiency in managing large-scale, growth-oriented organizations.

    At LQDA, his strategic oversight is complemented by his participation in various committees, including Compensation, Research and Development, and Litigation, reflecting his commitment to robust corporate governance and operational excellence.

    $LQDA Performance Under Roger A. Jeffs

    Past Roles

    OrganizationRoleDate RangeDetails
    Liquidia Corporation Research and Development Committee Member April 2021 - January 2022 Served on R&D Committee
    Liquidia Corporation Litigation Committee Member April 2021 - January 2022 Served on Litigation Committee
    Liquidia Corporation Compensation Committee Member November 2020 - December 2021 Served on Compensation Committee
    Liquidia Corporation Board Member November 2020 - January 2022 Appointed as condition to merger transaction
    RareGen Director August 2018 - November 2020 Merged with Liquidia
    United Therapeutics Corporation Director of Research, Development, and Medical 1998 - 2001 Joined during inception phase
    United Therapeutics Corporation President and Chief Operating Officer 2001 - 2014 Oversaw clinical development and regulatory approval
    United Therapeutics Corporation President and co-CEO 2015 - 2016 Helped lead IPO and managed commercial effort
    United Therapeutics Corporation Board Member 2001 - 2016 Served on board during tenure
    Amgen, Inc. Clinical development roles N/A Held various roles in clinical development
    Burroughs Wellcome Co. Clinical development roles N/A Held roles in clinical development

    External Roles

    OrganizationRoleDate RangeDetails
    Kriya Therapeutics Co-Founder and Vice Chairman Since October 2019 Gene therapy company
    Axsome Therapeutics, Inc. (Nasdaq: AXSM) Board Member N/A Biopharmaceutical company

    Fixed Compensation

    Data from  FY 2024
    Component NameAmount (USD)Payment ScheduleAdditional Details
    Salary$800,000 Annually Base salary for fiscal year 2024
    Stock Awards$5,533,450 Annually Granted as restricted stock units per ASC Topic 718
    All Other Compensation$14,580 Per-payroll Contributions to 401(k) plan and health savings account

    Performance Compensation

    Data from  FY 2024

    No information available on performance compensation for 2024